Poland
BIOTON S.A., operating under the slogan "Biotechnologia w trosce o pacjenta", is a leading European biotech company based in Poland and established in 1989. The company specializes in the production of human insulin, both as active pharmaceutical ingredients and in finished forms like cartridges and vials.
With a strong track record of over two decades, BIOTON S.A. holds a dominant position in the Polish market and is recognized among the top eight global commercial manufacturers of recombinant human insulin. The company emphasizes innovation through continuous investment in Polish biotechnology, leveraging local collaborations to commercialize Biotech Transfer results successfully.
Further enhancing its portfolio, BIOTON S.A. offers contract manufacturing (CMO/CDMO) and quality control (QC) services, adhering to the highest standards of Quality by Design (QbD) and current Good Manufacturing Practices (cGMP). The company also integrates pioneering therapeutic solutions for diabetes and supplies gastroenterological Foods for Special Medical Purposes (FSMP).
The last significant funding occurred on 01 July 2015 through a Private Equity Round led by CEE Equity Partners, highlighting investor confidence. While BIOTON S.A. strides forward with its expansive industry engagements spanning biopharma, biotechnology, and other sectors, it remains a promising opportunity for discerning investors looking to be part of a transformative journey in healthcare innovation.
